Valuation: Beam Therapeutics Inc.

Market Cap 2.71B 2.34B 2.2B 2B 3.76B 259B 3.82B 25.81B 10.12B 130B 10.17B 9.95B 432B P/E 2026 *
-6.13x
P/E 2027 * -5.68x
Enterprise Value 1.79B 1.55B 1.46B 1.32B 2.49B 172B 2.53B 17.08B 6.69B 85.86B 6.73B 6.58B 286B EV / Sales 2026 *
36.9x
EV / Sales 2027 * 23.7x
Free-Float
98.63%
Yield 2026 *
-
Yield 2027 * -
1 day-3.30%
1 week-2.23%
Current month+2.86%
1 month-0.30%
3 months-2.09%
6 months-4.75%
Current year-5.30%
1 week 25.71
Extreme 25.71
27.49
1 month 24.67
Extreme 24.67
28.47
Current year 21.63
Extreme 21.63
38.26
1 year 15.6
Extreme 15.6
38.26
3 years 13.52
Extreme 13.525
49.5
5 years 13.52
Extreme 13.525
116.91
10 years 13
Extreme 13
138.52
Manager TitleAgeSince
Chief Executive Officer 48 01/01/2017
Director of Finance/CFO 48 19/12/2024
President 57 24/01/2020
Director TitleAgeSince
Director/Board Member 48 01/01/2017
Director/Board Member 75 01/05/2018
Director/Board Member 56 10/10/2019
Date Insider Type Main position Quantity % Market Cap.
27/07/26 Sell

Chief Technology Officer

-16,667 0.0162%
30/06/26 Fiscal year

Chief Executive Officer

75,000 0.0729%
30/06/26 Sell

Chief Technology Officer

-373 0.0004%
Change 5-day change 1-year change 3-year change Capi.($)
-3.25%-2.23%+53.51%+12.47% 2.71B
-0.11%-1.67%+1.80%+19.90% 48.84B
+1.49%+4.28%+488.04%+623.63% 45.44B
+1.59%+2.43%+15.24%+90.62% 41.22B
+0.47%-0.58%+25.90%+13.29% 39.71B
-2.74%-2.74%+17.30%+56.10% 32.6B
+1.98%-0.88% - - 16.25B
-1.21%-2.50%+27.53%+136.44% 16.67B
-0.49%-0.34%+3.45%+29.14% 14.08B
-1.62%+0.06%+79.76%+41.87% 13.68B
Average -0.40%-0.77%+79.17%+113.72% 27.12B
Weighted average by Cap. +0.11%-0.84%+102.88%+151.77%

Financials

2026 *2027 *
Net sales 48.57M 41.95M 39.47M 35.87M 67.47M 4.65B 68.46M 463M 181M 2.33B 182M 178M 7.75B 62.75M 54.2M 50.99M 46.34M 87.17M 6.01B 88.44M 598M 234M 3.01B 236M 230M 10.02B
Net income -462M -399M -375M -341M -642M -44.25B -651M -4.4B -1.73B -22.13B -1.73B -1.7B -73.72B -537M -463M -436M -396M -745M -51.41B -756M -5.11B -2B -25.71B -2.01B -1.97B -85.64B
Net Debt -916M -791M -745M -677M -1.27B -87.8B -1.29B -8.73B -3.42B -43.91B -3.44B -3.37B -146B -1.22B -1.06B -993M -902M -1.7B -117B -1.72B -11.64B -4.56B -58.54B -4.59B -4.49B -195B
Logo Beam Therapeutics Inc.
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
Employees
540
Date Price Change Volume
18/08/26 $26.25 -3.14% 652,281
17/08/26 $27.10 +1.31% 1,470,184
14/08/26 $26.75 +0.91% 1,229,787
13/08/26 $26.51 -0.75% 2,021,807
12/08/26 $26.71 -0.52% 1,554,142
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
27.10USD
Average target price
52.15USD
Spread / Average Target
+92.45%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BEAM Stock